Table 1.
Baseline characteristics of patients with hand OA who received placebo in the two randomized controlled trials
| Baseline characteristics | RCT 1 (n = 102) |
RCT 2 (n = 41) |
p-value |
|---|---|---|---|
| Age, years | 59.2 ± 8.0 | 61.7 ± 18.9 | 0.305 |
| Female, n (%) | 95 (93.1) | 39 (95.1) | 0.496 |
| Weight, kg | 59.1 ± 8.0 | 60.4 ± 8.9 | 0.398 |
| Height, cm | 157.0 ± 6.0 | 156.0 ± 6.3 | 0.348 |
| Body mass index, kg/m2 | 23.9 ± 2.9 | 24.7 ± 2.8 | 0.129 |
| Duration of hand OA, months | 31.5 ± 47.7 | 60.4 ± 61.1 | 0.009 |
| Baseline | |||
| AUSCAN pain score (1–100) | 47.8 ± 19.8 | 48.9 ± 25.9 | 0.788 |
| AUSCAN stiffness score (1–100) | 60.6 ± 21.7 | 63.9 ± 27.6 | 0.504 |
| AUSCAN function score (1–100) | 45.7 ± 23.7 | 41.7 ± 27.1 | 0.382 |
| Patient global assessment (1–100) | 49.6 ± 15.9 | 60.8 ± 19.4 | 0.002 |
| Physician global assessment (1–100) | 41.0 ± 13.0 | 42.6 ± 10.5 | 0.471 |
| Tender joint count | 6.3 ± 5.1 | 5.5 ± 5 | 0.400 |
| Swollen joint count | 0.9 ± 2.4 | 0.0 ± 0.3 | 0.000 |
| Palpable node count | 5.2 ± 2.5 | N/A | |
| Deformed joint count | 2.0 ± 1.7 | N/A | |
| Erythrocyte sedimentation rate, mm/hr | 12.9 ± 9.4 | 16.1 ± 11.6 | 0.086 |
| hs-CRP, mg/dL (normal < 0.5 mg/dL) | 0.12 ± 0.26 | 0.21 ± 0.76 | 0.317 |
| Prior treatment, n (%) | N/A | ||
| Acetaminophen/Tramadol | 10 (9.8) | ||
| Acetaminophen | 1 (1.0) | ||
| NSAIDs | 36 (35.3) | ||
| Glucosamine | 13 (12.7) | ||
| Diacerein | 3 (2.9) | ||
| Others | 3 (2.9) | ||
Data are presented as the mean (SD) or n (%). AUSCAN Australian/Canadian Osteoarthritis Hand Index; CRP C-reactive protein, ESR Erythrocyte sedimentation rate, N/A Not available, NSAID Non-steroidal anti-inflammatory drug, OA Osteoarthritis, RCT Randomized controlled trial.